Trial Profile
A Phase Ila Exploratory 2-stage Design Study of CPC634 (CriPec Docetaxel) Monotherapy in Subjects With Platinum Resistant Ovarian Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 Aug 2023
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms CINOVA
- Sponsors Cristal Therapeutics
- 07 Aug 2023 Status changed to discontinued, according to Results published in the International Journal of Gynecological Cancer.
- 07 Aug 2023 Results assessing therapeutic effect of CPC634 in patients with platinum-resistant ovarian cancer, published in the International Journal of Gynecological Cancer.
- 14 Nov 2020 This trial has been completed in Netherlands as per European Clinical Trials Database record.